The long-term cost-effectiveness of obesity prevention interventions: Systematic literature review

Obesity Reviews

Volumn 13, Issue 6, 2012, Pages 537-553

  Lehnert, T ^a,b   Sonntag, D ^a,b   Konnopka, A ^a   Riedel Heller, S ^b,c   Konig H H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cost effectiveness; Decision analysis; Obesity prevention; Population health

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ENVIRONMENTAL FACTOR; HEALTH BEHAVIOR; HEALTH CARE DELIVERY; HUMAN; INTERVENTION STUDY; LONG TERM CARE; OBESITY; PREVENTIVE MEDICINE; RISK FACTOR; SIMULATION; SYSTEMATIC REVIEW;

ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; CALORIC RESTRICTION; COST-BENEFIT ANALYSIS; HUMANS; OBESITY; PUBLIC HEALTH; QUALITY-ADJUSTED LIFE YEARS;

EID: 84860888676     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00980.x     Document Type: Article

References (138)

1. Sassi F. Obesity and the Economics of Prevention. Fit Not Fat. OECD Publishing: Paris, 2010.
2. Sampsel S, May J. Assessment and management of obesity and comorbid conditions. Dis Manag 2007; 10: 252-265.
3. Bray GA. Etiology and pathogenesis of obesity. Clin Cornerstone 1999; 2: 1-15.
4. Lenz M, Richter T, Mühlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Ärztebl Int 2009; 106: 641-648.
5. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589.
6. World Health Organization. Obesity and overweight, 2011. [WWW document]. URL (accessed April 2011).
7. Lee WW. An overview of pediatric obesity. Pediatr Diabetes 2007; 8(Suppl. 9): 76-87.
8. Bleich S, Cutler D, Murray C, Adams A. Why is the developed world obese? Annu Rev Public Health 2008; 29: 273-295.
9. Finkelstein EA, Strombotne KL. The economics of obesity. Am J Clin Nutr 2010; 91: 1520s-1524s.
10. Philipson TJ, Posner RA. The long-run growth in obesity as a function of technological change. Perspect Biol Med 2003; 46: S87-S107.
11. James WP. The fundamental drivers of the obesity epidemic. Obes Rev 2008; 9(Suppl. 1): 6-13.
12. Swinburn BA, Sacks G, Hall KD etal. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814.
13. Swinburn B, Egger G, Raza F. Dissecting obesogenic environments: the development and application of a framework for identifying and prioritizing environmental interventions for obesity. Prev Med 1999; 29: 563-570.
14. Huneault L, Mathieu ME, Tremblay A. Globalization and modernization: an obesogenic combination. Obes Rev 2011; 12: e64-e72.
15. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr 1997; 66(4 Suppl.): 1044-1050.
16. Hu FB. Obesity and mortality: watch your waist, not just your weight. Arch Intern Med 2007; 167: 875-876.
17. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293: 1861-1867.
18. Ells LJ, Lang R, Shield JP etal. Obesity and disability - a short review. Obes Rev 2006; 7: 341-345.
19. Gregg EW, Guralnik JM. Is disability obesity's price of longevity? JAMA 2007; 298: 2066-2067.
20. Kushner RF, Foster GD. Obesity and quality of life. Nutrition 2000; 16: 947-952.
21. Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev 2001; 2: 219-229.
22. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2010; 12: 131-141.
23. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev 2011; 12: 50-61.
24. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825.
25. Quesenberry CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158: 466-472.
26. Peytremann-Bridevaux I, Santos-Eggimann B. Use of preventive services of overweight and obese Europeans aged 50-79 years. J Gen Intern Med 2007; 22: 923-929.
27. Detournay B, Fagnani F, Phillippo M etal. Obesity morbidity and health care costs in France: an analysis of the 1991-1992 Medical Care Household Survey. Int J Obes Relat Metab Disord 2000; 24: 151-155.
28. Finkelstein EA, Fiebelkorn IC, Wang GJ. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff 2003; 22: W219-WW26.
29. Thompson WG, Cook DA, Clark MM, Bardia A, Levine JA. Treatment of obesity. Mayo Clin Proc 2007; 82: 93-101.
30. Kissane NA, Pratt JS. Medical and surgical treatment of obesity. Best Pract Res Clin Anaesthesiol 2011; 25: 11-25.
31. Padwal R, Klarenbach S, Wiebe N etal. Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med 2011; 26: 1183-1194.
32. Loveman E, Frampton GK, Shepherd J etal. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. Health Technol Assess 2011; 15: 1-182.
33. World Health Organization. Intervention on diet and physical activity: what works, 2009. [WWW document]. URL (accessed June 2011).
34. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003; 26: 1.
35. Kelly MP, McDaid D, Ludbrook A, Powell J. Economic appraisal of public health interventions, 2005. [WWW document]. URL (accessed July 2011).
36. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Serv Res Policy 2008; 13(Suppl. 3): 23-30.
37. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press: Oxford, 2005.
38. Gray A. Applied Methods of Cost-Effectiveness Analysis in Health Care. Oxford University Press: Oxford, 2011.
39. Ganann R, Ciliska D, Thomas H. Expediting systematic reviews: methods and implications of rapid reviews. Implement Sci 2010; 9: 10-19.
40. Watt A, Cameron A, Sturm L etal. Rapid reviews versus full systematic reviews: an inventory of current methods and practice in health technology assessment. Int J Technol Assess Health Care 2008; 24: 133-139.
41. Buxton MJ, Drummond MF, Van Hout BA etal. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-227.
42. Briggs A, Claxton K, Sculpher M. Decision Modelling Health Economic Evaluation. Oxford University Press: Oxford, 2006.
43. Levy DT, Mabry PL, Wang YC etal. Simulation models of obesity: a review of the literature and implications for research and policy. Obes Rev 2010; 12: 378-394.
44. Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 2005; 21: 1073-1079.
45. Alton V, Eckerlund I, Norlund A. Health economic evaluations: how to find them. Int J Technol Assess Health Care 2006; 22: 512-517.
46. Robinson R. Cost-utility analysis. BMJ 1993; 2: 859-862.
47. Broome J. QALYs. J Public Econ 1993; 50: 149-167.
48. Murray CJ, Acharya AK. Understanding DALYs (disability-adjusted life years). J Health Econ 1997; 16: 703-730.
49. Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health 2002; 23: 115-134.
50. Klarenbach S, Padwal R, Wiebe N etal. Bariatric Surgery for Severe Obesity: Systematic Review and Economic Evaluation. Canadian Agency for Drugs and Technologies in Health: Ottawa, 2010.
51. Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg 2005; 200: 270-278.
52. Castaneda-Gonzalez L, Camberos-Solis R, Bacardi-Gascon M, Jimenez-Cruz A. Long-term randomized clinical trials of pharmacological treatment of obesity: systematic review. Colomb Med 2010; 41: 17-25.
53. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002; 6: 1-97.
54. Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011; 123: 34-44.
55. OECD. OECD health data: economic references, 2011. [WWW document]. URL (accessed June 2011).
56. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
57. Bemelmans W, van Baal P, Wendel-Vos W etal. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. Prev Med 2008; 46: 127-132.
58. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 2007; 30: 128-134.
59. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet 2010; 20: 1775-1784.
60. Cobiac L, Vos T, Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Aust N Z J Public Health 2010; 34: 240-247.
61. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med 2009; 14: e1000110.
62. Dalziel K, Segal L, Elley CR. Cost utility analysis of physical activity counselling in general practice. Aust N Z J Public Health 2006; 30: 57-63.
63. Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obes (Lond) 2011; 35: 1071-1078.
64. Galani C, Schneider H, Rutten FF. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 2007; 52: 372-382.
65. Magnus A, Haby MM, Carter R, Swinburn B. The cost-effectiveness of removing television advertising of high-fat and/or high-sugar food and beverages to Australian children. Int J Obes (Lond) 2009; 33: 1094-1102.
66. Moodie M, Haby M, Galvin L, Swinburn B, Carter R. Cost-effectiveness of active transport for primary school children - walking school bus program. Int J Behav Nutr Phys Act 2009; 6: 63.
67. Moodie M, Haby M, Wake M, Gold L, Carter R. Cost-effectiveness of a family-based GP-mediated intervention targeting overweight and moderately obese children. Econ Hum Biol 2008; 6: 363-376.
68. Moodie M, Haby MM, Swinburn B, Carter R. Assessing cost-effectiveness in obesity: active transport program for primary school children - TravelSMART Schools Curriculum program. J Phys Act Health 2011; 8: 503-515.
69. Moodie ML, Carter RC, Swinburn BA, Haby MM. The cost-effectiveness of Australia's active after-school communities program. Obesity (Silver Spring) 2010; 18: 1585-1592.
70. Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight loss interventions in overweight and obese women. Obesity (Silver Spring) 2006; 14: 1093-1106.
71. Roux L, Pratt M, Tengs TO etal. Cost effectiveness of community-based physical activity interventions. Am J Prev Med 2008; 35: 578-588.
72. Sacks G, Veerman JL, Moodie M, Swinburn B. 'Traffic-light' nutrition labelling and 'junk-food' tax: a modelled comparison of cost-effectiveness for obesity prevention. Int J Obes (Lond) 2010; 35: 1001-1009.
73. Trueman P, Haynes SM, Felicity Lyons G etal. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract 2010; 64: 775-783.
74. van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 2008; 11: 1033-1040.
75. Weinstein MC, O'Brien B, Hornberger J etal. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6: 9-17.
76. Byford S, Raftery J. Perspectives in economic evaluation. BMJ 1998; 16: 1529-1530.
77. Carter R, Moodie M, Markwick A, Magnus A, Vos T, Swinburn B. Assessing Cost-Effectiveness in Obesity (ACE-Obesity): an overview of the ACE approach, economic methods and cost results. BMC Public Health 2009; 9: 419.
78. Sacks G, Swinburn B, Lawrence M. Obesity policy action framework and analysis grids for a comprehensive policy approach to reducing obesity. Obes Rev 2009; 10: 76-86.
79. Berkel LA, Poston WS, Reeves RS, Foreyt JP. Behavioral interventions for obesity. J Am Diet Assoc 2005; 105(5 Suppl. 1): S35-S43.
80. Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity. Endocrinol Metab Clin North Am 2008; 37: 905-922.
81. Reever MM. Cognitive-behavioral interventions for obesity. Northeast Fla Med 2009; 59: 37-40.
82. Economos CD, Irish-Hauser S. Community interventions: a brief overview and their application to the obesity epidemic. J Law Med Ethics 2007; 35: 131-137.
83. Scheffler R, Durham M, McGuire T, Wells KB. Policy intervention. Ment Health Serv Res 2002; 4: 215-222.
84. Rose GA. The Strategy of Preventive Medicine. Oxford University Press: Oxford, 1992.
85. Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment - an overview and guide. Pharmacoeconomics 2008; 26: 131-148.
86. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 2011; 342: d1766.
87. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
88. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
89. Sassi F, Hurst J. The prevention of lifestyle-related chronic diseases: an economic framework, 2008. [WWW document]. URL (accessed June 2011).
90. National Institute for Health and Clinical Practice. Obesity guidance on prevention, identification, assessment and management of overweight and obesity in adults and children, 2006. [WWW document]. URL (accessed July 2011).
91. Roberts MG, Tobias MI. The use of multistate life-table models for improving population health. IMA J Math Appl Med Biol 2001; 18: 119-130.
92. Barendregt JJ, Van Oortmarssen GJ, Van Hout BA, Van Den Bosch JM, Bonneux L. Coping with multiple morbidity in a life table. Math Popul Stud 1998; 7: 29-49.
93. Sonnenberg FA, Beck JR. Markov-models in medical decision-making - a practical guide. Med Decis Making 1993; 13: 322-338.
94. Carter R, Moodie M, Markwick A etal. Assessing cost-effectiveness in obesity (ACE-Obesity): an overview of the ACE approach, economic methods and cost results. BMC Public Health 2009; 9: 419.
95. Vos T, Carter R, Mihalopoulos C, Veerman JL, Magnus A, Cobiac LJ. Assessing cost-effectiveness in prevention (ACE-Prevention): final report: University of Queensland, Brisbane. [WWW document]. URL (accessed May 2011).
96. Van Baal P, Feenstra TL, Hoogenveen R, de Wit GA. Cost effectiveness analysis with the RIVM chronic disease model, 2005. [WWW document]. URL (accessed June 2011).
97. Haby MM, Vos T, Carter R etal. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project. Int J Obes (Lond) 2006; 30: 1463-1475.
98. Hoogenveen RT, de Hollander AEM, van Genugten M. The chronic disease modelling approach, 1998. [WWW document]. URL (accessed June 2011).
99. Swinburn BA, Jolley D, Kremer PJ, Salbe AD, Ravussin E. Estimating the effects of energy imbalance on changes in body weight in children. Am J Clin Nutr 2006; 83: 859-863.
100. Thow AM, Jan S, Leeder S, Swinburn B. The effect of fiscal policy on diet, obesity and chronic disease: a systematic review. Bull World Health Organ 2010; 88: 609-614.
101. Centre of Evidence Based Medicine (CEBM). Levels of evidence, (March 2009). [WWW document]. URL (accessed August 2011).
102. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415.
103. Barte JC, ter Bogt NC, Bogers RP etal. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev 2010; 11: 899-906.
104. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343-345.
105. Bridges JFP, Onukwugha E, Mullins CD. Healthcare rationing by proxy cost-effectiveness analysis and the misuse of the $50, 000 threshold in the US. Pharmacoeconomics 2010; 28: 175-184.
106. Sassi F, Cecchini M, Lauer JA, Chisholm D. Improving lifestyles, tackling obesity: the health and economic impact of prevention strategies: OECD working paper No.48. 2009.
107. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004; 3: 39-41.
108. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 2005; 24: 751-773.
109. Miller WC. How effective are traditional dietary and exercise interventions for weight loss? Med Sci Sports Exerc 1999; 31: 1129-1134.
110. Koepsell TD, Wagner EH, Cheadle AC etal. Selected methodological issues in evaluating community-based health promotion and disease prevention programs. Annu Rev Public Health 1992; 13: 31-57.
111. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64.
112. Gortmaker SL, Swinburn BA, Levy D etal. Changing the future of obesity: science, policy, and action. Lancet 2011; 378: 838-847.
113. Heinrich S, Rapp K, Rissmann U, Becker C, Konig HH. Cost of falls in old age: a systematic review. Osteoporos Int 2010; 21: 891-902.
114. van Baal PH, Polder JJ, de Wit GA etal. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med 2008; 5: e29.
115. Rappange DR, van Baal PH, van Exel NJ, Feenstra TL, Rutten FF, Brouwer WB. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26: 815-830.
116. Van Baal PHM, Feenstra TL, Hoogenveen RT, De Wit GA, Brouwer WBF. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Econ 2007; 16: 421-433.
117. Garber AM, Phelps CE. Future costs and the future of cost-effectiveness analysis. J Health Econ 2008; 27: 819-821.
118. Garber AM, Phelps C. Economic foundations of cost-effectiveness analysis. NBER working paper w4146. Cambridge, MA, 1992.
119. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31.
120. Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004; 13: 417-427.
121. Manns B, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ 2003; 12: 949-958.
122. Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health 2010; 7: 3150-3195.
123. Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to promote fruit and vegetable consumption. PLoS ONE 2010; 5: e14148.
124. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 2010; 53: 875-881.
125. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 16: 251-264.
126. Lindgren P, Lindström J, Tuomilehto J etal. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 2007; 23: 177-183.
127. Gillies CL, Lambert PC, Abrams KR etal. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 24: 1180-1185.
128. Herman WH, Hoerger TJ, Brandle M etal. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 1: 323-332.
129. Ackermann RT, Marrero DG, Hicks KA etal. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care 2006; 29: 1237-1241.
130. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ 2011; 343: d4044.
131. Centre for Reviews and Dissemination. Systematic reviews. Guidance for undertaking reviews in health care: University of York: CRD, 2008.
132. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 7: 42-46.
133. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ 2010; 19: 43-55.
134. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24: 1043-1053.
135. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011; 31: 675-692.
136. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment - A review and consolidation of quality assessment. Pharmacoeconomics 2006; 24: 355-371.
137. Paisley S. Classification of evidence in decision-analytic models of cost-effectiveness: a content analysis of published reports. Int J Technol Assess Health Care 2010; 26: 458-462.
138. Brown WJ, Hockey R, Dobson A. Rose revisited: a 'middle road' prevention strategy to reduce noncommunicable chronic disease risk. Bull World Health Organ 2007; 85: 886-887.